This site is intended for UK Healthcare professionals only

This site is intended for UK healthcare professionals only



3 May, 2023

Testosterone patch for menopause

A company born out of ground-breaking research at The University of Warwick has raised almost £3 million of to develop a testosterone patch for people suffering from low libido and reduced zest for life due to the menopause.

Medherant, founded by University of Warwick’s, Professor David Haddleton, is aiming to begin clinical trials of this pioneering treatment in Autumn 2023. Medherant is ultimately aiming to get approval for clinical use, subject to a successful trial.

Assuming trials go well, this would be the only testosterone replacement patch available globally and introduced first in the UK.

Whilst oestrogen and progesterone HRT patches are available, there is currently no transdermal delivery patch available for testosterone delivery for women suffering from adverse symptoms from the menopause. Testosterone is an essential hormone for women and its production declines in post-menopausal people.

David Haddleton, Professor of Chemistry at the University of Warwick and Medherant’s founder said: “This is a very exciting development for us – the potential of this technology to improve women’s lives is huge. The work we’re doing at Medherant and at Warwick isn’t just theoretical, but instead aimed at a problem women are facing which can drastically affect their everyday lives and jobs.”

“This could deliver a product that is much needed and is just not available. With the technology already proven to work we can use our new patch to remove needless misery from women’s daily lives. We hope this will transform life for those suffering from post-menopause issues nationally, and indeed globally”.

Since 2015, Menopause Guidelines issued by National Institute for Health and Care Excellence (NICE) recommend that testosterone supplementation be considered for menopausal people with low sexual desire if hormone replacement therapy alone is not effective.

However, there are no currently approved testosterone products specifically for women. Currently, women seeking treatment for the effects of menopause on libido cannot be prescribed testosterone on the NHS, with many having to use irregular doses of gel only approved for use on men.

This new patch is intended to address this gap in menopause products, providing specific treatment that can be made widely available.


Latest news

NICE publishes updated draft menopause guideline

NICE has published its updated menopause guideline for public consultation. The draft guideline lays out clearly the risks and benefits of taking HRT that can be used to help people when they are discussing whether to start HRT with their clinician. Detailed tables...

Government survey seeks women’s views on reproductive health

Women in England are being encouraged to help shape reproductive health policy by sharing their experiences, in a new government survey. Delivering on a key commitment in the Women’s Health Strategy, the Women’s Reproductive Health Survey seeks women’s views across...

HFEA ‘State of the Fertility Sector’ report

The Human Fertilisation and Embryology Authority’s (HFEA) State of the Fertility Sector 2022/23 report reveals that out of the almost 100,000 treatment and storage cycles which took place, more than 99% were conducted without any incidents occurring. The annual report...

PCWHF welcomes new Chair

The PCWHF is delighted to announce the appointment of a new Chair. Following Dr Anne Connolly MBE’s decision to step away from the role she’s held since its inception, Dr Julie Oliver has been announced as her successor.  The PCWHF was founded by Dr Anne Connolly MBE...